Company Filing History:
Years Active: 2017
Title: The Innovative Work of Isabella Toller in Tumor Treatment
Introduction
Isabella Toller, an accomplished inventor based in Zurich, Switzerland, is making significant contributions to the field of cancer treatment through her innovative discoveries. With a notable patent under her belt, she is dedicated to the development of molecules that target tumor cells effectively.
Latest Patents
Isabella Toller's most recent patent, titled "Binding Molecules with Antitumoral Activity," presents a groundbreaking approach to cancer treatment. This invention introduces a binding molecule designed to specifically target two different epitopes of an antigen expressed on tumor cells. The molecule comprises a first binding polypeptide derived from Fyn SH3 that attaches to one epitope and a second binding polypeptide binding to another epitope. The patent also covers the nucleic acid molecule encoding the binding molecule, a vector incorporating the nucleic acid, and a host cell transformed with this vector. Additionally, her invention includes methods for producing these binding molecules and their applications in pharmaceutical and diagnostic compositions aimed at treating tumors.
Career Highlights
Isabella is part of Covagen AG, a company that focuses on developing therapeutic proteins and innovative biologics. Her work not only showcases her expertise as an inventor but also emphasizes her commitment to advancing medical science through practical applications of her research.
Collaborations
Throughout her career, Isabella has collaborated with other talented individuals in her field, including coworkers Simon Brack and Frédéric Mourlane. Their combined efforts promote an environment of innovation and excellence, fostering advancements in therapeutic options for patients battling cancer.
Conclusion
Isabella Toller exemplifies the spirit of innovation and dedication in the field of cancer research. Her patent for binding molecules with antitumoral activity represents a significant stride in medical science, potentially transforming treatment protocols for tumor cells. Through her work at Covagen AG and her collaborative efforts with esteemed colleagues, she continues to push the boundaries of what is possible in cancer therapy.